Intravitreal Bevacizumab for Prevention of Early Postvitrectomy Hemorrhage in Diabetic Patients. A Randomized Clinical Trial

Ophthalmology

Volumn 116, Issue 10, 2009, Pages 1943-1948

  Ahmadieh, Hamid ^a   Shoeibi, Nasser ^a   Entezari, Morteza ^a   Monshizadeh, Ramin ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Medical Consultants of Southern California Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY; VITREOUS HEMORRHAGE;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITRECTOMY; VITREOUS BODY; VITREOUS HEMORRHAGE; YOUNG ADULT;

EID: 70349440840     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.07.001     Document Type: Article

References (22)

1. Schachat A.P., Oyakawa R.T., Michels R.G., and Rice T.A. Complications of vitreous surgery for diabetic retinopathy. II. Postoperative complications. Ophthalmology 90 (1983) 522-530
2. de Bustros S., Glaser B.M., Michels R.G., and Auer C. Effect of epsilon-aminocaproic acid on post-vitrectomy hemorrhage. Arch Ophthalmol 103 (1985) 219-221
3. Ramezani A.R., Ahmadieh H., Ghaseminejad A.K., et al. Effect of tranexamic acid on early post-vitrectomy diabetic haemorrhage; a randomised clinical trial. Br J Ophthalmol 89 (2005) 1041-1044
4. Laatikainen L., Summanen P., and Immonen I. Effect of tranexamic acid on post-vitrectomy haemorrhage in diabetic patients. Int Ophthalmol 10 (1987) 153-155
5. Verdoorn C., and Hendrikse F. Intraocular human thrombin infusion in diabetic vitrectomies. Ophthalmic Surg 20 (1989) 278-279
6. Packer A.J., McCuen II B.W., Hutton W.L., et al. Procoagulant effects of intraocular sodium hyaluronate (Healon) after phakic diabetic vitrectomy: a prospective, randomized study. Ophthalmology 96 (1989) 1491-1494
7. Bodanowitz S., Kir N., and Hesse L. Silicone oil for recurrent vitreous hemorrhage in previously vitrectomized diabetic eyes. Ophthalmologica 211 (1997) 219-222
8. Joondeph B.C., and Blankenship G.W. Hemostatic effects of air versus fluid in diabetic vitrectomy. Ophthalmology 96 (1989) 1701-1706
9. Koutsandrea C.N., Apostolopoulos M.N., Chatzoulis D.Z., et al. Hemostatic effects of SF6 after diabetic vitrectomy for vitreous hemorrhage. Acta Ophthalmol Scand 79 (2001) 34-38
10. Yang C.M., Yeh P.T., and Yang C.H. Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology 114 (2007) 710-715
11. Spaide R.F., and Fisher Y.L. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26 (2006) 275-278
12. Ahmadieh H., Moradian S., and Malihi M. Rapid regression of extensive retinovitreal neovascularization secondary to branch retinal vein occlusion after a single intravitreal injection of bevacizumab. Int Ophthalmol 26 (2005) 191-193
13. Avery R.L., Pearlman J., Pieramici D.J., et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113 (2006) 1695
14. Moradian S., Ahmadieh H., Malihi M., et al. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 246 (2008) 1699-1705
15. Jorge R., Costa R.A., Calucci D., et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 26 (2006) 1006-1013
16. Romano M.R., Gibran S.K., Marticorena J., et al. Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage?. Eye 19 (2009) 618-621
17. Rizzo S., Genovesi-Ebert F., Di Bartolo E., et al. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 246 (2008) 837-842
18. Diabetic Retinopathy Vitrectomy Study (DRVS). Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Report no 1. Ophthalmology 92 (1985) 492-502
19. Ishikawa K., Honda S., Tsukahara Y., and Negi A. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye 23 (2009) 108-111
20. Kuiper E.J., Van Nieuwenhoven F.A., de Smet M.D., et al. The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS ONE 16 (2008) e2675
21. Arevalo J.F., Maia M., Flynn Jr. H.W., et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92 (2008) 213-216
22. Schachat A.P., Chambers W.A., Liesegang T.J., and Albert D.A. Safe and effective. Ophthalmology 110 (2003) 2073-2074